Report
Adam Fleck
EUR 100.00 For Business Accounts Only

A Continued Competitive Environment Presenting Near-Term Challenges for Mayne Pharma

No-moat-rated Mayne reported a first-half result below our expectations, despite improvement on the previous corresponding period, or pcp, across key metrics. This included a 13% increase in revenue on the pcp to AUD 274.4 million, a 16% increase in underlying EBITDA to AUD 81.2 million, and a 35% increase in underlying net profit after tax to AUD 21.1 million, with all slightly under our full-year expectations.
Except for the highly competitive generic products division, or GPD, all segments ex...
Underlying
Mayne Pharma Group Limited

Mayne Pharma is a pharmaceutical company focused on applying its drug delivery capabilities to commercialize branded and generic pharmaceuticals. Co. operates in four business units: Generic Products, which develops, manufactures, markets and distributes generic pharmaceutical products in the U.S.; Specialty Brands, which markets and distributes specialty branded pharmaceutical products in the U.S.; Metrics Contract Services, which provides contract pharmaceuticals development services and analytical services to third parties; and Mayne Pharma International, which develops, manufactures, markets and distributes branded and generic pharmaceutical products globally, excluding the U.S.

Provider
Morningstar
Morningstar

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.

Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.

We have operations in 27 countries.

Analysts
Adam Fleck

Other Reports on these Companies
Other Reports from Morningstar

ResearchPool Subscriptions

Get the most out of your insights

Get in touch